CELEBREX (celecoxib) by Viatris (2) is cyclooxygenase inhibitors [moa]. First approved in 1998.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
CELEBREX (celecoxib) is an oral nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing inflammation and pain. It is indicated for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute pain in adults. The drug has been a cornerstone NSAID therapy for over 25 years, offering improved gastrointestinal tolerability compared to non-selective NSAIDs.
Product is in mature/LOE-approaching phase with modest Part D spending ($16M in 2023); brand teams should expect resource constraints and focus on retention and lifecycle management rather than aggressive growth initiatives.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.
Worked on CELEBREX at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CELEBREX offers limited growth trajectory given its LOE-approaching status and mature market position; this role is best suited for professionals seeking stability in established product management or those building expertise in lifecycle management and generic transition strategy. Career development is constrained by declining commercial investment, making it a transitional or consolidation role rather than a high-visibility growth opportunity.